Incyte stock trades at EUR 110.18 after an Atebrioz target hike
Published on 09/29/2026 at 12:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Incyte stock (ISIN US45337C1027) was trading at EUR 110.18 at Lang & Schwarz on September 29, 2026 at 12:46 p.m. CEST, plus 0.36 percent versus the EUR 109.78 prior close. The immediate catalyst is a new USD 152.00 analyst target after the approval of Atebrioz.
Atebrioz adds a cash milestone
According to Investing.com on September 28, 2026, H.C. Wainwright raised its price target from USD 150.00 to USD 152.00 and maintained a Buy rating. The firm cited FDA approval of Atebrioz, which triggers a USD 25.00 million payment to Incyte and leaves the company eligible for royalties and further milestone payments.
The approval gives the target revision a concrete financial anchor rather than relying only on pipeline expectations. H.C. Wainwright also estimated USD 205.00 million to USD 225.00 million in near-term gross economics before taxes, transaction costs, royalties and future milestones.
Quarterly growth raises the bar
MarketBeat reported that Incyte generated USD 1.67 billion in Q2 2026 revenue, up 37.70 percent from the prior-year quarter. Quarterly EPS was USD 3.09 versus consensus of USD 2.15, a USD 0.94 beat.
The same report put net margin at 27.71 percent and described the company as a biopharmaceutical group focused on oncology and inflammatory diseases. That combination of revenue growth and earnings conversion explains why analyst targets remain close to the stock's primary-market level, even as the euro quotation reflects a separate trading venue.
Incyte stock holds above prior close
Incyte stock was trading at EUR 110.18 at Lang & Schwarz on September 29, 2026 at 12:46 p.m. CEST, plus 0.36 percent versus the EUR 109.78 prior close. The primary NASDAQ quote was last at USD 124.82 on September 28, 2026 at 4:00 p.m. ET; the 52-week range was USD 82.82 to USD 132.60, while market capitalization stood at USD 25.3 billion.
Incyte stock facts
- Company: Incyte Corporation
- ISIN: US45337C1027
- Ticker: INCY
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of September 29, 2026, 12:46 p.m. CEST): EUR 110.18
- Change versus prior close: plus 0.36 percent
- Prior close Lang & Schwarz (September 28, 2026): EUR 109.78
- Market capitalization: USD 25.3 billion (as of September 28, 2026)
- 52-week range: USD 82.82-132.60 (as of September 28, 2026)
